advantage multi 9 solution
elanco canada limited - imidacloprid; moxidectin - solution - 40mg; 4mg - imidacloprid 40mg; moxidectin 4mg - cats; mammals(miscellaneous)
advantage multi 55 solution
elanco canada limited - imidacloprid; moxidectin - solution - 250mg; 62.5mg - imidacloprid 250mg; moxidectin 62.5mg - dogs
advantage multi 20 solution
elanco canada limited - imidacloprid; moxidectin - solution - 100mg; 25mg - imidacloprid 100mg; moxidectin 25mg - dogs
advantage multi 10 solution
elanco canada limited - imidacloprid; moxidectin - solution - 40mg; 10mg - imidacloprid 40mg; moxidectin 10mg - dogs
advantage multi 100 solution
elanco canada limited - imidacloprid; moxidectin - solution - 400mg; 100mg - imidacloprid 400mg; moxidectin 100mg - dogs
np thyroid 60- levothyroxine, liothyronine tablet
preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 38 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su
np thyroid 30- levothyroxine, liothyronine tablet
preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 19 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su
np thyroid 120- levothyroxine, liothyronine tablet
preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 76 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su
np thyroid 90- levothyroxine, liothyronine tablet
preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 57 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su
np thyroid 30- levothyroxine, liothyronine tablet
preferred pharmaceuticals inc - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. contraindications: thyroid hormone preparations are generally co